CTRI/2022/01/039594尚未招募未知
Prospective, open-label, single-arm, multicentre, observational, postmarketing clinical study to evaluate safety and performance of multifocal hydrophobic acrylic foldable intraocular lens (IOL) (Omni Lens Pvt. Ltd.) in patients who require IOL implantation during routine cataract surgery. - NA
Omni Lens Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1. Patient aged greater than or equal to 40 years at the time of enrolment
- •2. A patient who receive multifocal hydrophobic acrylic foldable IOL (Omni Lens Pvt. Ltd.) as per the instruction mentioned in instructions
- •for use (IFU) of the study device during routine cataract surgery
- •3. Clear intraocular media other than cataract
- •4. Calculated IOL power is within the range of the study device
- •5. The patient or his/her legally authorized representative (if applicable)
- •agrees to provide written informed consent
- •6. The patient is willing to comply with protocol specified follow-up
- •evaluations
排除标准
- •1. Patient with contraindications for Multifocal IOL mentioned in the
- •IFU of the study device
- •2. previous intraocular or corneal surgery
- •3. traumatic cataract
- •4. pregnancy or lactation
- •5. instability of keratometry or biometry measurements
- •6. irregular astigmatism
- •7. more than 1 D of pre-operative corneal astigmatism
- •8. Currently participating in another clinical study with experimental
- •drugs or devices
- •9. Unsuitable for study participation for any other reason, as determined
- •by Investigators clinical judgment (reason to be documented on CRF)
- •10. Active SARS-CoV-2 infection known to Patient at the time of
- •enrolment in the study/ patients having signs and symptoms of SARSCoV-
- •2 infection at the time of enrolment
- •Patients shall be discontinued when certain conditions are present at the time
- •of surgery, including:
- •zonular instability;
- •need for iris manipulation;
- •capsular fibrosis or other opacity; and
- •inability to fixate IOL in the desired position.
- •In such cases, the patient shall be followed until the condition has stabilized.
研究者
相似试验
尚未招募
不适用
Safety and performance of Intraocular LensCTRI/2022/01/039593Omni Lens Pvt Ltd
招募中
不适用
Prospective, open-label, multicenter, single-arm, post-marketingstudy to assess the performance and safety of Vliwasorb® Prowound healingDRKS00031365ohmann & Rauscher GmbH & Co.KG135
进行中(未招募)
1 期
Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment periodEUCTR2014-000162-22-DEaboratoire HRA Pharma70
进行中(未招募)
1 期
Study to assess the effects of metyrapone in patients with Cushing?s syndrome during a 12-week treatment periodTreatment of Cushing?s syndromeMedDRA version: 17.1Level: PTClassification code 10011652Term: Cushing's syndromeSystem Organ Class: 10014698 - Endocrine disordersEUCTR2014-000162-22-ESaboratoire HRA Pharma70
进行中(未招募)
1 期
Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment periodTreatment of Cushing’s syndromeMedDRA version: 20.0 Level: PT Classification code 10011652 Term: Cushing's syndrome System Organ Class: 10014698 - Endocrine disordersEUCTR2014-000162-22-PLaboratoire HRA Pharma55
